19. Treatment outcome of macrolide-resistant Mycoplasma Pneumoniae pneumonia in children
Main Article Content
Abstract
Mycoplasma Pneumoniae (MP) is a main pathogenic cause of community-acquired pneumonia in children over 5 years old. Currently, macrolide is the first-choice antibiotic for treatment. There have been no study in Vietnam on the incidence and results of treatment of pneumonia infected with macrolide-resistant MPs in children. This study aims to "Evaluate the results of treatment of pneumonia infected with macrolide-resistant MP in children". This is a prospective descriptive study of a group of patients with pneumonia infected with MP from July 2021 to June 2023 at the National Children's Hospital. The results showed that the rate of pneumonia infected with MPs carrying macrolide resistance genes accounted for 69.9%, the average hospital stay was 7.5 ± 3.1 days, of which 76.4% of patients infected with MPs carried resistance genes. Macrolides have a clinical response to macrolide treatment. Thus, pneumonia infected with MP carrying macrolide resistance genes in children accounts for a large proportion, however most of them still respond to macrolides clinically.
Article Details
Keywords
Macrolide-resistant, mycoplasma pneumoniae, children
References
2. Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017;30(3):747-809. doi:10.1128/CMR.00114-16
3. Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. Journal of Microbiology, Immunology and Infection. 2021;54(4):557-565. doi:10.1016/j.jmii.2020.10.002
4. Yang TI, Chang TH, Lu CY, et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? Journal of Microbiology, Immunology and Infection. 2019;52(2):329-335. doi:10.1016/j.jmii.2018.09.009
5. Zhou Y, Zhang Y, Sheng Y, et al. More Complications Occur in Macrolide-Resistant than in Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia. Antimicrob Agents Chemother. 2014;58(2):1034-1038. doi:10.1128/AAC.01806-13
6. Bébéar CM, Pereyre S. Mechanisms of drug resistance in Mycoplasma pneumoniae. Curr Drug Targets Infect Disord. 2005;5(3):263-271. doi:10.2174/1568005054880109
7. Dumke R, Von Baum H, Lück PC, et al. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clinical Microbiology and Infection. 2010;16(6):613-616. doi:10.1111/j.1469-0691.2009.02968.x
8. Peuchant O, Ménard A, Renaudin H, et al. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. Journal of Antimicrobial Chemotherapy. 2009;64(1):52-58. doi:10.1093/jac/dkp160
9. Wang Y, Qiu S, Yang G, et al. An Outbreak of Mycoplasma pneumoniae Caused by a Macrolide-Resistant Isolate in a Nursery School in China. Antimicrob Agents Chemother. 2012;56(7):3748-3752. doi:10.1128/AAC.0014 2-12
10. Liu Y, Ye X, Zhang H, et al. Antimicrobial Susceptibility of Mycoplasma pneumoniae Isolates and Molecular Analysis of Macrolide-Resistant Strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160-2162. doi:10.1128/AAC.01684-08
11. Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future Microbiol. 2008;3(6):635-648. doi:10.2217/17460913.3.6.635
12. Lee E, Cho HJ, Hong SJ, et al. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60(5):151-157. doi:10.3345/kjp. 2017.60.5.151
13. Lê Thị Hồng Hanh, Nguyễn Duy Bộ. Một số đặc điểm lâm sàng, cận lâm sàng và kết quả điều trị trẻ viêm phổi do Mycoplasma Pneumoniae tại Bệnh viện Nhi Trung ương năm 2015-2016. Tạp chí Phòng chống bệnh sốt rét và các bệnh ký sinh trùng. 2016;93(4).
14. Chen YC, Hsu WY, Chang TH. Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia. Emerg Infect Dis. 2020;26(7):1382-1391. doi:10.3201/eid2607.200017